2. Signaling Pathways
  3. Apoptosis
  4. Ferroptosis

Ferroptosis

Ferroptosis

Ferroptosis

Related Products

PDF 0.68 MB

Ferroptosis is a non-apoptotic form of regulated cell death. It is distinct from other regulated cell death phenotypes, such as apoptosis and necroptosis. Ferroptosis is characterized by extensive lipid peroxidation, which can be suppressed by iron chelators or lipophilic antioxidants. Mechanistically, Ferroptosis inducers are divided into two classes: (1) inhibitors of cystine import via system xc− (e.g., Erastin), which subsequently causes depletion of glutathione (GSH), and (2) covalent inhibitors (e.g., (1S, 3R)-RSL3) of glutathione peroxidase 4 (GPX4). Since GPX4 reduces lipid hydroperoxides using GSH as a co-substrate, both compound classes ultimately result in loss of GPX4 activity, followed by elevated levels of lipid reactive oxygen species (ROS) and consequent cell death.

Ferroptosis is an iron- and ROS-dependent form of regulated cell death (RCD). Misregulated Ferroptosis has been implicated in multiple physiological and pathological processes, including cancer cell death, neurotoxicity, neurodegenerative diseases, acute renal failure, drug-induced hepatotoxicity, hepatic and heart ischemia/reperfusion injury, and T-cell immunity.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-B1346R
    DL-Glutamine (Standard)
    		Inhibitor
    DL-Glutamine (Standard) is the analytical standard for DL-Glutamine. This product is intended for research and analytical applications. DL-Glutamine is used for biochemical research and drug synthesis.
    DL-Glutamine (Standard)
  • HY-B0581R
    Dexrazoxane (Standard)
    		Inhibitor
    Dexrazoxane (Standard) is the analytical standard of Dexrazoxane. This product is intended for research and analytical applications. Dexrazoxane, as an intracellular iron chelating agent, reduces the formation of superoxide radicals and has cardioprotective, anti-inflammatory, antioxidant, anti-tumor and neuroprotective activities. Dexrazoxane inhibits ferroptosis of H9c2 cells by inhibiting HMGB1. Dexrazoxane induces DNA damage and apoptosis in human fibrosarcoma cells .
    Dexrazoxane (Standard)
  • HY-W012352R
    2-Hydroxyanthraquinone (Standard)
    		Inducer
    2-Hydroxyanthraquinone (Standard) is the analytical standard of 2-Hydroxyanthraquinone (HY-W012352). This product is intended for research and analytical applications. 2-Hydroxyanthraquinone is a product generated by the photochemical oxidation of Anthracene (ANT) (HY-Y0299). 2-Hydroxyanthraquinone induces ferroptosis in cardiomyocytes by depleting GSH and inhibiting GPX4, leading to cardiac developmental malformations. 2-Hydroxyanthraquinone causes damage to the cerebrovascular system and blood-brain barrier in zebrafish by downregulating the Wnt/β-catenin signaling pathway, as well as inducing inflammation and neuronal apoptosis. 2-Hydroxyanthraquinone can be used in studies related to cerebrovascular diseases and cardiotoxicity.
    2-Hydroxyanthraquinone (Standard)
  • HY-D3447
    LPd peroxida probe-2
    		99.17%
    LPd peroxida probe-2 (Compound I-1) is a lipid peroxidation fluorescent indicator (Ex = 488 nm, Em = 535 nm). LPd peroxida probe-2 undergoes fluorescence spectral changes in response to lipid hydroperoxides and can be used for Ferroptosis detection and cell imaging.
    LPd peroxida probe-2
  • HY-W018161R
    Hexadecanedioic acid (Standard)
    Hexadecanedioic acid (Thapsic acid) (Standard) is the analytical standard of Hexadecanedioic acid (HY-W018161). This product is intended for research and analytical applications. Hexadecanedioic acid is an orally active metabolite produced by B. uniformis. Hexadecanedioic acid inhibits IRE1α-XBP1s-mediated flipogenesis and ferroptosis. Hexadecanedioic acid downregulates XBP1 and Hrd1 expression, activates the Nrf2/SLC7A11/GPX4 pathway. Hexadecanedioic acid can be used for the research of metabolic-associated fatty liver disease.
    Hexadecanedioic acid (Standard)
  • HY-16762R
    Artefenomel (Standard)
    		Activator
    Artefenomel (Standard) is the analytical standard of Artefenomel. This product is intended for research and analytical applications. Artefenomel (OZ439) is an orally active, synthetic anti-malarial compound containing an artemisinin pharmacophore with a mechanism of action similar to that of artemisinin. Artefenomel has antiviral activity against SARS-CoV-2.
    Artefenomel (Standard)
  • HY-50898S4
    Lapatinib-d7
    		Activator
    Lapatinib-d7 (GW572016-d7) is deuterium labeled Lapatinib. Lapatinib (GW572016) is a potent, orally active inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC50 values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively.
    Lapatinib-d<sub>7</sub>
  • HY-17359S1
    Deferasirox-13C6
    		Inhibitor
    Deferasirox-13C6 (ICL 670-13C6) is 13C labeled Deferasirox. Deferasirox (ICL 670) is an orally available iron chelator used for the management of transfusional iron overload.
    Deferasirox-<sup>13</sup>C<sub>6</sub>
  • HY-113308AS1
    Taurolithocholic Acid-d5 sodium
    		Inhibitor
    Taurolithocholic Acid-d5 (sodium) is the deuterium labeled Taurolithocholic acid sodium salt. Taurolithocholic Acid sodium salt is an orally active bile acid and antiviral agent. Taurolithocholic Acid sodium salt upregulates FADS2 by activating the TGR5-PI3K/AKT-SREBP2 signaling axis, inhibits SFTSV-induced ferroptosis, viral replication and viral entry of HBV/HDV, while reducing the release of IL-1β, lipid ROS and LDH. While exerting antiviral protective effects, Taurolithocholic Acid sodium salt also stimulates the recycling of hepatocellular membrane transporters, impairs canalicular bile acid secretion function, and induces hepatocyte cholestasis, apoptosis and acute hepatocellular injury. Taurolithocholic Acid sodium salt serves as an experimental model compound for hepatocellular cholestasis. At concentrations ≤200 μM, Taurolithocholic Acid sodium salt shows no cytotoxicity and does not activate the interferon pathway. Taurolithocholic Acid sodium salt not only protects mice from lethal SFTSV infection but also is suitable for studies related to severe fever with thrombocytopenia syndrome and cholestasis.
    Taurolithocholic Acid-d<sub>5</sub> sodium
  • HY-10284S4
    Linagliptin-d5
    		Inhibitor
    Linagliptin-d5 (BI 1356-d5) is deuterium labeled Linagliptin. Linagliptin is a highly potent, selective DPP-4 inhibitor with IC50 of 1 nM.
    Linagliptin-d<sub>5</sub>
  • HY-14291S5
    Vildagliptin-d6
    		Inhibitor
    Vildagliptin-d6 (LAF237-d6 ) is deuterium labeled Vildagliptin. Vildagliptin (LAF237) is a potent, stable, selective dipeptidyl peptidase IV (DPP-IV) inhibitor with an IC50 of 3.5 nM in human Caco-2 cells. Vildagliptin possesses excellent oral bioavailability and potent antihyperglycemic activity.
    Vildagliptin-d<sub>6</sub>
  • HY-12298R
    Setanaxib (Standard)
    		Inhibitor
    Setanaxib (Standard) is the analytical standard of Setanaxib. This product is intended for research and analytical applications. Setanaxib (GKT137831) is a selective NADPH oxidase (NOX1/4) inhibitor with Kis of 140 and 110 nM, respectively.
    Setanaxib (Standard)
  • HY-B0450AR
    Ciclopirox olamine (Standard)
    		Inhibitor
    Ciclopirox (olamine) (Standard) is the analytical standard of Ciclopirox (olamine). This product is intended for research and analytical applications. Ciclopirox olamine (Ciclopirox ethanolamine) is a synthetic and orally active antifungal agent that can be used for superficial mycoses reseaech. Ciclopirox olamine has a very broad spectrum of activity and inhibits dermatophytes, yeasts, molds, and many Gram-positive and Gram-negative species pathogenic. Ciclopirox olamine also has anticancer and anti-inflammatory effect.
    Ciclopirox olamine (Standard)
  • HY-168768
    FerroLOXIN-1
    		Inhibitor
    FerroLOXIN-1 is a potent inhibitor of 15LOX-2 that selectively blocked production of pro-ferroptotic HOO-ETE-PE and protected against RSL3-induced ferroptosis. FerroLOXIN-1 closely interacted therein with 15LOX-2 only, and in particular with Y154, N155, W158.
    FerroLOXIN-1
  • HY-120912R
    Gingerenone A (Standard)
    		Activator
    Gingerenone A (Standard) is the analytical standard of Gingerenone A. This product is intended for research and analytical applications. Gingerenone A is an Nrf2-Gpx4 activator that can induce Ferroptosis in liver damage with oral activity. Gingerenone A has anti-inflammatory, anti-diabetic, anti-tumor, and pro-aging effects in mice.
    Gingerenone A (Standard)
  • HY-F0003AR
    NADPH tetracyclohexanamine (Standard)
    		Inhibitor
    NADPH (tetracyclohexanamine) (Standard) is the analytical standard of NADPH (tetracyclohexanamine). This product is intended for research and analytical applications. 0
    NADPH tetracyclohexanamine (Standard)
  • HY-103157R
    PD146176 (Standard)
    		Activator
    PD146176 (Standard) is the analytical standard of PD146176. This product is intended for research and analytical applications. PD146176 (NSC168807), a 15-Lipoxygenase (15-LO) inhibitor, inhibits rabbit reticulocyte 15-LO (Ki=197 nM, IC50=0.54 μM). PD146176 reverses cognitive impairment, brain amyloidosis, and tau pathology by stimulating autophagy in aged triple transgenic mice.
    PD146176 (Standard)
Cat. No. Product Name / Synonyms Application Reactivity
All Rights Reserved.
Download Ferroptosis Signaling Pathway Map.